Bioavailability of nafarelin in healthy volunteers.

Chaplin MD

American journal of obstetrics and gynecology1 Feb 1992Cited by 10 (Europe PMC)

PMID1531580DOI10.1016/0002-9378(92)91710-rPepBankPUB-01531580

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy women, intravenous nafarelin reached maximum concentration at 2 minutes.
In plain wordsIn healthy women, intravenous nafarelin reached its highest concentration at 2 minutes.
Peptide
Nafarelin
Outcome
Not applicableIntravenous Tmax
Study
n = 15
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 micrograms · intravenousAs given in this study (human).
Measurements
Tmax
2 minutes
intravenous
Source sentences
Summary
After intravenous administration, time to maximum concentration (Tmax) was 2 minutes, and maximum serum concentration (Cmax) was 8.2 +/- 2.09 (SD) ng/ml.
2 context sentences(design, population, supporting numbers)
Summary · context
The bioavailability of a single dose of intranasal nafarelin was evaluated in 15 healthy female volunteers.
Summary · context
Each subject received a 400 micrograms intranasal and a 25 micrograms intravenous dose of nafarelin separated by at least 7 days.
Report a problemFND-0153158001
02HumanNon-randomized trialPharmacokinetics
In healthy women, intravenous nafarelin had a maximum serum concentration of 8.2 +/- 2.09 ng/ml.
In plain wordsIn healthy women, intravenous nafarelin had a maximum serum concentration of 8.2 +/- 2.09 ng/ml.
Peptide
Nafarelin
Outcome
Not applicableIntravenous Cmax
Study
n = 15
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 micrograms · intravenousAs given in this study (human).
Measurements
Cmax
8.2 ng/ml
mean
Cmax SD
2.09 ng/ml
intravenous
Source sentences
Summary
After intravenous administration, time to maximum concentration (Tmax) was 2 minutes, and maximum serum concentration (Cmax) was 8.2 +/- 2.09 (SD) ng/ml.
2 context sentences(design, population, supporting numbers)
Summary · context
The bioavailability of a single dose of intranasal nafarelin was evaluated in 15 healthy female volunteers.
Summary · context
Each subject received a 400 micrograms intranasal and a 25 micrograms intravenous dose of nafarelin separated by at least 7 days.
Report a problemFND-0153158002
03HumanNon-randomized trialPharmacokinetics
In healthy women, intranasal nafarelin had mean Tmax 18.4 +/- 7.9 minutes, ranging from 5 to 40 minutes.
In plain wordsIn healthy women, intranasal nafarelin reached its highest concentration after 18.4 minutes on average.
Peptide
Nafarelin
Outcome
Not applicableIntranasal Tmax
Study
n = 15
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
400 micrograms · intranasalAs given in this study (human).
Measurements
Tmax
18.4 minutes
mean
Tmax SD
7.9 minutes
intranasal
Tmax range
5 to 40 minutes
intranasal
Source sentences
Summary
For intranasal nafarelin, mean Tmax was 18.4 +/- 7.9 minutes (range, 5 to 40 minutes), and Cmax was 2.04 +/- 1.29 ng/ml (range, 0.49 to 5.7 ng/ml).
2 context sentences(design, population, supporting numbers)
Summary · context
The bioavailability of a single dose of intranasal nafarelin was evaluated in 15 healthy female volunteers.
Summary · context
Each subject received a 400 micrograms intranasal and a 25 micrograms intravenous dose of nafarelin separated by at least 7 days.
Report a problemFND-0153158003
04HumanNon-randomized trialPharmacokinetics
In healthy women, intranasal nafarelin had mean Cmax 2.04 +/- 1.29 ng/ml, ranging from 0.49 to 5.7 ng/ml.
In plain wordsIn healthy women, intranasal nafarelin reached a maximum concentration of 2.04 ng/ml on average.
Peptide
Nafarelin
Outcome
Not applicableIntranasal Cmax
Study
n = 15
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
400 micrograms · intranasalAs given in this study (human).
Measurements
Cmax
2.04 ng/ml
mean
Cmax SD
1.29 ng/ml
intranasal
Cmax range
0.49 to 5.7 ng/ml
intranasal
Source sentences
Summary
For intranasal nafarelin, mean Tmax was 18.4 +/- 7.9 minutes (range, 5 to 40 minutes), and Cmax was 2.04 +/- 1.29 ng/ml (range, 0.49 to 5.7 ng/ml).
2 context sentences(design, population, supporting numbers)
Summary · context
The bioavailability of a single dose of intranasal nafarelin was evaluated in 15 healthy female volunteers.
Summary · context
Each subject received a 400 micrograms intranasal and a 25 micrograms intravenous dose of nafarelin separated by at least 7 days.
Report a problemFND-0153158004
05HumanNon-randomized trialPharmacokinetics
In healthy women, nafarelin bioavailability averaged 2.82% +/- 1.23%, ranging from 1.15% to 5.62%.
In plain wordsIn healthy women, an average of 2.82% of intranasal nafarelin reached the circulation.
Peptide
Nafarelin
Outcome
Not applicableSystemic bioavailability
Study
n = 15
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
400 micrograms · intranasalAs given in this study (human).
Measurements
Bioavailability
2.82%
mean
Bioavailability SD
1.23%
intranasal
Bioavailability range
1.15 to 5.62%
intranasal
Source sentences
Summary
Systemic bioavailability of nafarelin ranged from 1.15% to 5.62% and averaged 2.82% +/- 1.23%.
2 context sentences(design, population, supporting numbers)
Summary · context
The bioavailability of a single dose of intranasal nafarelin was evaluated in 15 healthy female volunteers.
Summary · context
Each subject received a 400 micrograms intranasal and a 25 micrograms intravenous dose of nafarelin separated by at least 7 days.
Report a problemFND-0153158005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.